Molecular mechanisms involved in cisplatin cytotoxicity
暂无分享,去创建一个
[1] BARNETT ROSENBERG,et al. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.
[2] P. Lohman,et al. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques. , 1985, Carcinogenesis.
[3] S. Lippard,et al. Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II). , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Lippard,et al. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. , 1985, Biochemistry.
[5] S. Lippard,et al. Structural aspects of platinum anticancer drug interactions with DNA , 1987 .
[6] C. Sorenson,et al. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. , 1988, Cancer research.
[7] J. Reedijk,et al. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. , 1988, Cancer research.
[8] Stephen B. Howell. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.
[9] C. Job,et al. Transcription by eucaryotic and procaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). , 1991, Biochemistry.
[10] J. H. Vos,et al. Differential introduction of DNA damage and repair in mammalian genes transcribed by RNA polymerases I and II , 1991, Molecular and cellular biology.
[11] F. Muggia. Cisplatin update. , 1991, Seminars in oncology.
[12] A. Rahmouni,et al. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[13] K. Comess,et al. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. , 1992, Biochemistry.
[14] P. Hanawalt,et al. Lack of transcription-coupled repair in mammalian ribosomal RNA genes. , 1993, Biochemistry.
[15] S. Lippard,et al. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. , 1993, Science.
[16] V. Brabec,et al. DNA adducts of cisplatin, transplatin and platinum-intercalating drugs. , 1994, IARC scientific publications.
[17] D. K. Treiber,et al. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[18] S. Lippard,et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[19] J. Yu,et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.
[20] A. Harris,et al. Repair of cisplatin‐DNA adducts by protein extracts from human ovarian carcinoma , 1994, International journal of cancer.
[21] T. Jacks,et al. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.
[22] T. Moss,et al. Promotion and regulation of ribosomal transcription in eukaryotes by RNA polymerase I. , 1995, Progress in nucleic acid research and molecular biology.
[23] R. Weichselbaum,et al. Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents , 1995, Nature.
[24] A. Gronenborn,et al. Molecular basis of human 46X,Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex , 1995, Cell.
[25] J. Mymryk,et al. Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Lippard,et al. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). , 1995, Nucleic acids research.
[27] I. Barajon,et al. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. , 1995, Histology and histopathology.
[28] M. Pillaire,et al. Replication of DNA containing cisplatin lesions and its mutagenic consequences. , 1995, Biochimie.
[29] David A. Case,et al. Structural basis for DNA bending by the architectural transcription factor LEF-1 , 1995, Nature.
[30] S. Lippard,et al. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. , 1995, Biochemistry.
[31] S. Lippard,et al. Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.
[32] Shigenori Iwai,et al. Atomic model of a pyrimidine dimer excision repair enzyme complexed with a dna substrate: Structural basis for damaged DNA recognition , 1995, Cell.
[33] M. Smerdon,et al. Repair of UV damage in actively transcribed ribosomal genes. , 1995, Biochemistry.
[34] S. Lippard,et al. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.
[35] G. Inman,et al. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. , 1995, The EMBO journal.
[36] D. Lilley,et al. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[37] E. Friedberg. Relationships between DNA repair and transcription. , 1996, Annual review of biochemistry.
[38] M. Karin,et al. Three distinct signalling responses by murine fibroblasts to genotoxic stress , 1996, Nature.
[39] J. Essigmann,et al. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. , 1996, Chemistry & biology.
[40] R. Fuchs,et al. Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[41] J. Turchi,et al. Human Ku Autoantigen Binds Cisplatin-damaged DNA but Fails to Stimulate Human DNA-activated Protein Kinase* , 1996, The Journal of Biological Chemistry.
[42] A. Wang,et al. Structural studies of interactions between anticancer platinum drugs and DNA. , 1996, Progress in biophysics and molecular biology.
[43] C. Boland,et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. , 1996, Cancer research.
[44] E. Reed,et al. Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. , 1996, Cancer letters.
[45] L. Zon,et al. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat , 1996, Current Biology.
[46] S. Lippard,et al. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo. , 1996, Biochemistry.
[47] R. Brown,et al. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. , 1996, Cancer research.
[48] J. Schornagel,et al. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2 , 1996, Springer US.
[49] P. Modrich,et al. Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line* , 1996, The Journal of Biological Chemistry.
[50] S. Lippard,et al. Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.
[51] D. Moras,et al. Cisplatin‐ and UV‐damaged DNA lure the basal transcription factor TFIID/TBP , 1997, The EMBO journal.
[52] P. Karran,et al. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. , 1997, Nucleic acids research.
[53] M. Yamada,et al. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. , 1997, Nucleic acids research.
[54] W. Kaelin,et al. p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.
[55] T. Lindahl,et al. DNA excision repair pathways. , 1997, Current opinion in genetics & development.
[56] J. Hoeijmakers,et al. Cockayne syndrome: defective repair of transcription? , 1997, The EMBO journal.
[57] I. Roninson,et al. Identification of p53 genetic suppressor elements which confer resistance to cisplatin , 1997, Oncogene.
[58] F. Ali-Osman,et al. Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells. , 1997, Toxicology and applied pharmacology.
[59] S. Cannistra,et al. Enrichment for DNA mismatch repair‐deficient cells during treatment with cisplatin , 1998, International journal of cancer.
[60] S. Lippard,et al. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. , 1998, Biochemistry.
[61] C. Rudolph,et al. The High Mobility Group Domain Protein Cmb1 ofSchizosaccharomyces pombe Binds to Cytosines in Base Mismatches and Opposite Chemically Altered Guanines* , 1998, The Journal of Biological Chemistry.
[62] E. Raymond,et al. Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.
[63] S. Lippard,et al. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. , 1998, Biochemistry.
[64] B. Tsang,et al. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. , 1998, International journal of oncology.
[65] S. Lippard,et al. Telomere loss in cells treated with cisplatin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[66] R. Perona,et al. Cisplatin induces a persistent activation of JNK that is related to cell death , 1998, Oncogene.
[67] J. Zlatanova,et al. Proteins that specifically recognize cisplatin‐damaged DNA: a clue to anticancer activity of cisplatin , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[68] P. Jordan,et al. Cisplatin inhibits synthesis of ribosomal RNA in vivo. , 1998, Nucleic acids research.
[69] J. Essigmann,et al. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. , 1998, Biochemistry.
[70] T. Jacks,et al. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[71] T. Kunkel,et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.
[72] M. Beltrame,et al. Flexing DNA: HMG-box proteins and their partners. , 1998, American journal of human genetics.
[73] B. Viollet,et al. TATA Binding Protein Discriminates between Different Lesions on DNA, Resulting in a Transcription Decrease , 1998, Molecular and Cellular Biology.
[74] G. Strathdee,et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.
[75] G. Hirst,et al. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes , 1999, Current Biology.
[76] F. Allain,et al. Solution structure of the HMG protein NHP6A and its interaction with DNA reveals the structural determinants for non‐sequence‐specific binding , 1999, The EMBO journal.
[77] G. Marra,et al. Recognition of DNA alterations by the mismatch repair system. , 1999 .
[78] Reuven Agami,et al. Interaction of c-Abl and p73α and their collaboration to induce apoptosis , 1999, Nature.
[79] G. Marra,et al. Recognition of DNA alterations by the mismatch repair system. , 1999, The Biochemical journal.
[80] Antonio Costanzo,et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.
[81] R. Wood,et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours , 1999, Current Biology.
[82] C. Pabo,et al. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins , 1999, Nature.
[83] Jijie Gu,et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.